| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 151.86 | 115.15 | 76.30 | 69.93 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | 112.10 | — |
| 160.76 | 124.47 | 191.43 | 71.61 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 1.21 | 0.66 | 0.78 | 0.80 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 10.56 | 7.90 | 4.84 | 3.31 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.34) | (4.64) | — | — |
—
|
| ’25 | (4.19) | (14.79) | (10.56) | (7.08) |
(36.62)
|
| ’24 | (14.39) | (10.61) | (20.13) | (10.56) |
(55.70)
|
| ’23 | (34.66) | (19.56) | (14.43) | (13.38) |
(82.03)
|
| ’22 | (55.05) | (47.26) | (40.88) | (36.98) |
(180.16)
|
| ’21 | (17.73) | (32.22) | (29.39) | (42.79) |
(122.14)
|
| ’20 | (2.28) | (3.28) | (7.23) | (16.82) |
(29.62)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.34) | (4.64) | — | — |
—
|
| ’25 | (4.19) | (14.79) | (10.56) | (7.08) |
(36.62)
|
| ’24 | (14.39) | (10.61) | (20.13) | (10.56) |
(55.70)
|
| ’23 | (43.13) | (26.54) | (19.58) | (13.44) |
(102.69)
|
| ’22 | (75.29) | (73.40) | (66.08) | (49.99) |
(264.75)
|
| ’21 | (26.86) | (40.72) | (51.14) | (61.25) |
(179.97)
|
| ’20 | (3.25) | (3.55) | (11.54) | (62.09) |
(80.43)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.62) | (0.63) | — | — |
—
|
| ’25 | (4.32) | (3.24) | (2.01) | (1.21) |
(10.70)
|
| ’24 | (3.74) | (2.29) | (3.54) | (1.82) |
(11.39)
|
| ’23 | (8.80) | (2.80) | (10.40) | (1.99) |
(24.00)
|
| ’22 | (8.40) | (9.20) | (8.60) | (8.20) |
(34.40)
|
| ’21 | (13.20) | (5.40) | (6.60) | (8.60) |
(29.60)
|
| ’20 | (0.24) | (0.07) | (0.06) | — |
(5.89)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 9.42 | 6.08 | 7.28 | 10.17 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 379.40 | 18.54 | 92.00 | 42.79 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 192 | 49 | 14 | 17 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | ‡‡‡‡‡ | — | — | — | — | — | ‡‡‡‡‡ | — | — |
Revenue
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (225.25) | (156.09) | (74.13) | (71.37) | — | — | — |
EBT
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (223.18) | (156.09) | (74.13) | (71.37) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21.81 | 4.76 | 3.61 | 0.53 | — | — | — |
Depreciation
|
| — | — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (34.40) | (24.00) | (11.39) | (10.70) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (27.82) | (12.61) | (8.56) | (5.49) | — | — | — |
Cash Flow/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.06) | (3.18) | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (40.88) | (15.79) | (8.56) | (5.49) | — | — | — |
Free CF/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 56.15 | 34.72 | 26.03 | 17.08 | — | — | — |
Book Value/Sh
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.48 | 6.50 | 6.51 | 6.67 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | ‡‡‡ | — | — | — | — | — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | ‡‡‡‡‡ | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | ‡‡‡ | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | ‡‡‡‡‡ | — | — | — | — | — | ‡‡‡‡‡ | — | — |
EV/Sales
|
| — | — | — | — | ‡‡‡‡‡ | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (180.16) | (82.03) | (55.70) | (36.62) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (84.59) | (20.66) | — | — | — | — | — |
Capex
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (264.75) | (102.69) | (55.70) | (36.62) | — | — | — |
FCF
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 236.59 | 150.20 | 116.57 | 186.59 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | 74.73 | 81.43 | 84.19 | 84.81 | — | — | — |
Total Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (186.19) | (70.43) | (30.96) | 8.51 | — | — | — |
Net Debt
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 363.61 | 225.83 | 169.44 | 113.87 | — | — | — |
Sh' Equity
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (40.87%) | (38.65%) | (25.16%) | (30.56%) | — | — | — |
ROA
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (79.78%) | (64.02%) | (33.19%) | (40.13%) | — | — | — |
ROIC
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (48.58%) | (52.96%) | (37.51%) | (50.39%) | — | — | — |
ROE
|
Instil Bio (TIL), a trailblazing clinical-stage biotech harnessing tumor infiltrating lymphocyte (TIL) therapies for tough solid tumors like colorectal cancer, trades at multi-year lows around $8 after a staggering 98% plunge from its 2021 SPAC-fueled peak of $590. Yet, this depressed valuation screams opportunity: analysts’ mean price target implies a whopping 540% upside, with the high-end forecasting over 1,460% gains, far outpacing minimal downside risk. TIL’s razor-sharp pivot to its next-gen lead asset, ITIL-306, amid aggressive cost-cutting—slashing headcount 96% to just 14 employees and halting capex—has tamed cash burn by up to 46% while preserving a 12-18 month runway, setting the stage for explosive value creation if clinical catalysts deliver.
With zero revenue today but projections for $1.93 million in 2025 (a 14x leap), TIL mirrors the high-stakes biotech playbook where losses are narrowing dramatically—net income improved 52% to -$74 million in 2024, EPS less dilutive at -$11.39—and efficiency metrics like ROA and ROIC are ticking higher. Validated by peer successes like Iovance’s 2024 TIL approval that ignited sector rallies, TIL’s CRC focus taps an underserved market ripe for disruption, trading at a steep discount to $26 book value and lofty EV/Sales multiples that scream growth repricing.
Bottom line: TIL is a high-conviction speculative gem for oncology optimists, with Q1 2026 Phase 1 ITIL-306 data as the pivotal spark. Breakthrough here could catapult shares skyward; even modest milestones curb dilution fears in this binary bet poised for outsized returns.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.